Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of rencofilstat in adults with non-alcoholic steatohepatitis with fibrosis (NASH F3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis with Fibrosis

Drugs mentioned

• Rencofilstat (rencofilstat)

Snippet

Sponsor: Hepion Pharmaceuticals, Inc. | Conditions: NASH With Fibrosis | Phase 2 | Status: COMPLETED